Cargando…
Predicting 2-year survival in stage I-III non-small cell lung cancer: the development and validation of a scoring system from an Australian cohort
BACKGROUND: There are limited data on survival prediction models in contemporary inoperable non-small cell lung cancer (NSCLC) patients. The objective of this study was to develop and validate a survival prediction model in a cohort of inoperable stage I-III NSCLC patients treated with radiotherapy....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008968/ https://www.ncbi.nlm.nih.gov/pubmed/35418206 http://dx.doi.org/10.1186/s13014-022-02050-1 |
_version_ | 1784687175291371520 |
---|---|
author | Lee, Natalie Si-Yi Shafiq, Jesmin Field, Matthew Fiddler, Caroline Varadarajan, Suganthy Gandhidasan, Senthilkumar Hau, Eric Vinod, Shalini Kavita |
author_facet | Lee, Natalie Si-Yi Shafiq, Jesmin Field, Matthew Fiddler, Caroline Varadarajan, Suganthy Gandhidasan, Senthilkumar Hau, Eric Vinod, Shalini Kavita |
author_sort | Lee, Natalie Si-Yi |
collection | PubMed |
description | BACKGROUND: There are limited data on survival prediction models in contemporary inoperable non-small cell lung cancer (NSCLC) patients. The objective of this study was to develop and validate a survival prediction model in a cohort of inoperable stage I-III NSCLC patients treated with radiotherapy. METHODS: Data from inoperable stage I-III NSCLC patients diagnosed from 1/1/2016 to 31/12/2017 were collected from three radiation oncology clinics. Patient, tumour and treatment-related variables were selected for model inclusion using univariate and multivariate analysis. Cox proportional hazards regression was used to develop a 2-year overall survival prediction model, the South West Sydney Model (SWSM) in one clinic (n = 117) and validated in the other clinics (n = 144). Model performance, assessed internally and on one independent dataset, was expressed as Harrell’s concordance index (c-index). RESULTS: The SWSM contained five variables: Eastern Cooperative Oncology Group performance status, diffusing capacity of the lung for carbon monoxide, histological diagnosis, tumour lobe and equivalent dose in 2 Gy fractions. The SWSM yielded a c-index of 0.70 on internal validation and 0.72 on external validation. Survival probability could be stratified into three groups using a risk score derived from the model. CONCLUSIONS: A 2-year survival model with good discrimination was developed. The model included tumour lobe as a novel variable and has the potential to guide treatment decisions. Further validation is needed in a larger patient cohort. |
format | Online Article Text |
id | pubmed-9008968 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-90089682022-04-15 Predicting 2-year survival in stage I-III non-small cell lung cancer: the development and validation of a scoring system from an Australian cohort Lee, Natalie Si-Yi Shafiq, Jesmin Field, Matthew Fiddler, Caroline Varadarajan, Suganthy Gandhidasan, Senthilkumar Hau, Eric Vinod, Shalini Kavita Radiat Oncol Research BACKGROUND: There are limited data on survival prediction models in contemporary inoperable non-small cell lung cancer (NSCLC) patients. The objective of this study was to develop and validate a survival prediction model in a cohort of inoperable stage I-III NSCLC patients treated with radiotherapy. METHODS: Data from inoperable stage I-III NSCLC patients diagnosed from 1/1/2016 to 31/12/2017 were collected from three radiation oncology clinics. Patient, tumour and treatment-related variables were selected for model inclusion using univariate and multivariate analysis. Cox proportional hazards regression was used to develop a 2-year overall survival prediction model, the South West Sydney Model (SWSM) in one clinic (n = 117) and validated in the other clinics (n = 144). Model performance, assessed internally and on one independent dataset, was expressed as Harrell’s concordance index (c-index). RESULTS: The SWSM contained five variables: Eastern Cooperative Oncology Group performance status, diffusing capacity of the lung for carbon monoxide, histological diagnosis, tumour lobe and equivalent dose in 2 Gy fractions. The SWSM yielded a c-index of 0.70 on internal validation and 0.72 on external validation. Survival probability could be stratified into three groups using a risk score derived from the model. CONCLUSIONS: A 2-year survival model with good discrimination was developed. The model included tumour lobe as a novel variable and has the potential to guide treatment decisions. Further validation is needed in a larger patient cohort. BioMed Central 2022-04-13 /pmc/articles/PMC9008968/ /pubmed/35418206 http://dx.doi.org/10.1186/s13014-022-02050-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Lee, Natalie Si-Yi Shafiq, Jesmin Field, Matthew Fiddler, Caroline Varadarajan, Suganthy Gandhidasan, Senthilkumar Hau, Eric Vinod, Shalini Kavita Predicting 2-year survival in stage I-III non-small cell lung cancer: the development and validation of a scoring system from an Australian cohort |
title | Predicting 2-year survival in stage I-III non-small cell lung cancer: the development and validation of a scoring system from an Australian cohort |
title_full | Predicting 2-year survival in stage I-III non-small cell lung cancer: the development and validation of a scoring system from an Australian cohort |
title_fullStr | Predicting 2-year survival in stage I-III non-small cell lung cancer: the development and validation of a scoring system from an Australian cohort |
title_full_unstemmed | Predicting 2-year survival in stage I-III non-small cell lung cancer: the development and validation of a scoring system from an Australian cohort |
title_short | Predicting 2-year survival in stage I-III non-small cell lung cancer: the development and validation of a scoring system from an Australian cohort |
title_sort | predicting 2-year survival in stage i-iii non-small cell lung cancer: the development and validation of a scoring system from an australian cohort |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008968/ https://www.ncbi.nlm.nih.gov/pubmed/35418206 http://dx.doi.org/10.1186/s13014-022-02050-1 |
work_keys_str_mv | AT leenataliesiyi predicting2yearsurvivalinstageiiiinonsmallcelllungcancerthedevelopmentandvalidationofascoringsystemfromanaustraliancohort AT shafiqjesmin predicting2yearsurvivalinstageiiiinonsmallcelllungcancerthedevelopmentandvalidationofascoringsystemfromanaustraliancohort AT fieldmatthew predicting2yearsurvivalinstageiiiinonsmallcelllungcancerthedevelopmentandvalidationofascoringsystemfromanaustraliancohort AT fiddlercaroline predicting2yearsurvivalinstageiiiinonsmallcelllungcancerthedevelopmentandvalidationofascoringsystemfromanaustraliancohort AT varadarajansuganthy predicting2yearsurvivalinstageiiiinonsmallcelllungcancerthedevelopmentandvalidationofascoringsystemfromanaustraliancohort AT gandhidasansenthilkumar predicting2yearsurvivalinstageiiiinonsmallcelllungcancerthedevelopmentandvalidationofascoringsystemfromanaustraliancohort AT haueric predicting2yearsurvivalinstageiiiinonsmallcelllungcancerthedevelopmentandvalidationofascoringsystemfromanaustraliancohort AT vinodshalinikavita predicting2yearsurvivalinstageiiiinonsmallcelllungcancerthedevelopmentandvalidationofascoringsystemfromanaustraliancohort |